Expression of ERG protein in prostate cancer: Variability and biological correlates

Endocrine-Related Cancer

Volumn 22, Issue 3, 2015, Pages 277-287

  Ayala, Gustavo ^a   Frolov, Anna ^b,c   Chatterjee, Deyali ^c   He, Dandan ^c   Hilsenbeck, Susan ^b   Ittmann, Michael ^c,d  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Dan L Duncan Cancer Center   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

MYC; NF B; Prostate cancer; PTEN; TMPRSS2 ERG

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; S PHASE KINASE ASSOCIATED PROTEIN 2; SERUM RESPONSE FACTOR; SPROUTY PROTEIN; SPROUTY1 PROTEIN; STEROID RECEPTOR COACTIVATOR 1; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; SERINE PROTEINASE; TMPRSS2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BIOCHEMICAL RECURRENCE; ENZYME ACTIVATION; FUSION GENE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; BIOSYNTHESIS; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

BIOMARKERS, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TISSUE ARRAY ANALYSIS;

EID: 84937027953     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0586     Document Type: Article

References (67)

1. Agoulnik IU, Krause WC, Bingman WE III, Rahman HT, Amrikachi M, Ayala GE & Weigel NL 2003 Repressors of androgen and progesterone receptor action. Journal of Biological Chemistry 278 31136-31148. (doi:10.1074/jbc.M305153200)
2. Agoulnik IU, Vaid A, Bingman WE III, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM & Weigel NL 2005 Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Research 65 7959-7967. (doi:10.1158/0008-5472.CAN-04-3541)
3. Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE III, Erdem H, Frolov A, Smith CL, Ayala GE, Ittmann MM et al. 2006 Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Research 66 10594-10602. (doi:10.1158/0008-5472.CAN-06-1023)
4. Agoulnik IU, Hodgson MC, Bowden WA & Ittmann MM 2011 INPP4B: the new kid on the PI3K block. Oncotarget 2 321-328.
5. Allen JD, Verhoeven E, Domen J, van der Valk M & Berns A 1997 Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene 15 1133-1141. (doi:10.1038/sj.onc.1201288)
6. Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, Fedor HL, Carducci MA, De Marzo AM & Eisenberger MA 2012 An immuno-histochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer 118 6063-6071. (doi:10.1002/cncr.27689)
7. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, Wheeler M, Spitler J & Rowley DR 2003a Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clinical Cancer Research 9 4792-4801.
8. Ayala G, Wang D, Wulf G, Frolov A, Li R, Sowadski J, Wheeler TM, Lu KP & Bao L 2003b The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Research 63 6244-6251.
9. Ayala G, Thompson T, Yang G, Frolov A, Li R, Scardino P, Ohori M, Wheeler T & Harper W 2004 High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clinical Cancer Research 10 6572-6578. (doi:10.1158/1078-0432.CCR-04-0477)
10. Ayala G, Frolov A, Ittman M, Mohammed S, LeBlancM, Falcon S, Rowley D & Etzioni R 2013a Biological correlates of biochemical recurrence free survival using multiple markers in a large tissue microarray cohort. Annals of Clinical and Laboratory Science 43 11-21.
11. Ayala G, Morello M, Frolov A, You S, Li R, Rosati F, Bartolucci G, Danza G, Adam RM, Thompson TC et al. 2013b Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. Journal of Pathology 231 77-87. (doi:10.1002/path.4217)
12. Bassi C, Ho J, Srikumar T, Dowling RJ, GorriniC, Miller SJ, Mak TW, Neel BG, Raught B & Stambolic V 2013 Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 341 395-399. (doi:10.1126/science.1236188)
13. Brase JC, Johannes M, Mannsperger H, Falth M, Metzger J, Kacprzyk LA, Andrasiuk T, Gade S, Meister M, Sirma H et al. 2011 TMPRSS2-ERGspecific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. BMC Cancer 11 507. (doi:10.1186/1471-2407-11-507)
14. Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG et al. 2013 ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. Journal of Clinical Investigation 123 1109-1122. (doi:10.1172/JCI66666)
15. Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongvipat J et al. 2013 ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nature Medicine 19 1023-1029. (doi:10.1038/nm.3216)
16. Clinckemalie L, Spans L, Dubois V, Laurent M, Helsen C, Joniau S & Claessens F 2013 Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element. Molecular Endocrinology 27 2028-2040. (doi:10.1210/me.2013-1098)
17. Cordon-Cardo C, Kotsianti A, Verbel DA, Teverovskiy M, Capodieci P, Hamann S, Jeffers Y, Clayton M, Elkhettabi F, Khan FM et al. 2007 Improved prediction of prostate cancer recurrence through systems pathology. Journal of Clinical Investigation 117 1876-1883. (doi:10.1172/JCI31399)
18. Dai H, Li R, Wheeler T, Diaz de Vivar A, Frolov A, Tahir S, Agoulnik I, Thompson T, Rowley D & Ayala G 2005 Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate 65 276-286. (doi:10.1002/pros. 20294)
19. Ding Y, He D, Florentin D, Frolov A, Hilsenbeck S, Ittmann M, Kadmon D, Miles B, Rowley D & Ayala G 2013 Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clinical Cancer Research 19 6101-6111. (doi:10.1158/1078-0432.CCR-12-3669)
20. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, Rantala J, Alanen K, Nees M & Kallioniemi O 2010 FZD4 as a mediator of ERG oncogeneinduced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Research 70 6735-6745. (doi:10.1158/0008-5472.CAN-10-0244)
21. Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM & Shah RB 2009 Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Modern Pathology 22 1083-1093. (doi:10.1038/modpathol.2009.69)
22. Haqq C, Li R, Khodabakhsh D, Frolov A, Ginzinger D, Thompson T, Wheeler T, Carroll P & Ayala G 2005 Ethnic and racial differences in prostate stromal estrogen receptor a. Prostate 65 101-109. (doi:10.1002/pros.20272)
23. Hart M, Wach S, Nolte E, Szczyrba J, Menon R, Taubert H, Hartmann A, Stoehr R, Wieland W, Grasser FA et al. 2013 The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer. FEBS Journal 280 2105-2116. (doi:10.1111/febs.12236)
24. Hodgson MC, Shao LJ, Frolov A, Li R, Peterson LE, Ayala G, Ittmann MM, Weigel NL & Agoulnik IU 2011 Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Research 71 572-582. (doi:10.1158/0008-5472.CAN-10-2314)
25. King JC, Xu J, Wongvipat J, HieronymusH, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS et al. 2009 Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nature Genetics 41 524-526. (doi:10.1038/ng.371)
26. Kluth M, Harasimowicz S, Burkhardt L, Grupp K, Krohn A, Prien K, Gjoni J, Hass T, Galal R, Graefen M et al. 2014 Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer. International Journal of Cancer. Journal International du Cancer 135 1369-1380. (doi:10.1002/ijc.28784)
27. Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, GleaveME et al. 2005 Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. American Journal of Pathology 167 255-266. (doi:10.1016/S0002-9440(10)62970-7)
28. Kwabi-Addo B, Wang J, Erdem H, Vaid A, Castro P, Ayala G & Ittmann M 2004 The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Research 64 4728-4735. (doi:10.1158/0008-5472.CAN-03-3759)
29. Leinonen KA, Saramaki OR, Furusato B, Kimura T, Takahashi H, Egawa S, Suzuki H, Keiger K, Ho Hahm S, Isaacs WB et al. 2013 Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 22 2333-2344. (doi:10. 1158/1055-9965.EPI-13-0333-T)
30. Li R, YounesM, Frolov A, Wheeler TM, Scardino P, OhoriM& Ayala G 2003 Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Research 23 3413-3418.
31. Li R, Wheeler T, Dai H, Frolov A, Thompson T & Ayala G 2004a High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. American Journal of Surgical Pathology 28 928-934. (doi:10.1097/00000478-200407000-00013)
32. Li R, Younes M, Wheeler TM, Scardino P, Ohori M, Frolov A & Ayala G 2004b Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 58 193-199. (doi:10.1002/pros. 10321)
33. Li R, Wheeler TM, Dai H, Sayeeduddin M, Scardino PT, Frolov A & Ayala GE 2006 Biological correlates of p27 compartmental expression in prostate cancer. Journal of Urology 175 528-532. (doi:10.1016/S0022-5347(05)00151-5)
34. Li R, Erdamar S, Dai H, Wheeler TM, Frolov A, Scardino PT, Thompson TC & Ayala GE 2007 Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Human Pathology 38 1501-1507. (doi:10.1016/j.humpath.2007.02.016)
35. Li R, Dai H, Wheeler TM, Sayeeduddin M, Scardino PT, Frolov A & Ayala GE 2009a Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology. Clinical Cancer Research 15 3568-3573. (doi:10.1158/1078-0432.CCR-08-0826)
36. Li R, Erdamar S, Dai H, Sayeeduddin M, Frolov A, Wheeler TM & Ayala GE 2009b Cytoplasmic accumulation of glycogen synthase kinase-3b is associated with aggressive clinicopathological features in human prostate cancer. Anticancer Research 29 2077-2081.
37. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, Hood L & Nelson PS 1999 Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Research 59 4180-4184.
38. Magistroni V, Mologni L, Sanselicio S, Reid JF, Redaelli S, Piazza R, Viltadi M, Bovo G, Strada G, Grasso M et al. 2011 ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells. PLoS ONE 6 e28162. (doi:10.1371/journal.pone.0028162)
39. Massoner P, Kugler KG, Unterberger K, Kuner R, Mueller LA, Falth M, Schafer G, Seifarth C, Ecker S, Verdorfer I et al. 2013 Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y. PLoS ONE 8 e55207. (doi:10.1371/journal.pone.0055207)
40. McAlhany SJ, Ayala GE, Frolov A, Ressler SJ, Wheeler TM, Watson JE, Collins C & Rowley DR 2004 Decreased stromal expression and increased epithelial expression of WFDC1/ps20 in prostate cancer is associated with reduced recurrence-free survival. Prostate 61 182-191. (doi:10.1002/pros.20085)
41. Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM & Shah RB 2007 Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Research 67 7991-7995. (doi:10.1158/0008-5472.CAN-07-2043)
42. Mertz KD, Horcic M, HailemariamS, D'AntonioA, Dirnhofer S, Hartmann A, Agaimy A, Eppenberger-Castori S, Obermann E, Cathomas G et al. 2013 Heterogeneity of ERG expression in core needle biopsies of patients with early prostate cancer. Human Pathology 44 2727-2735. (doi:10.1016/j.humpath.2013.07.019)
43. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Muller J, Scholz L et al. 2011 ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clinical Cancer Research 17 5878-5888. (doi:10.1158/1078-0432.CCR-11-1251)
44. Minner S, Gartner M, Freudenthaler F, Bauer M, Kluth M, Salomon G, Heinzer H, Graefen M, Bokemeyer C, Simon R et al. 2013 Marked heterogeneity of ERG expression in large primary prostate cancers. Modern Pathology 26 106-116. (doi:10.1038/modpathol.2012.130)
45. Nakka M, Agoulnik IU & Weigel NL 2013 Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. International Journal of Biochemistry & Cell Biology 45 763-772. (doi:10.1016/j.biocel.2012.12.012)
46. O'Hurley G, Prencipe M, Lundon D, O'Neill A, Boyce S, O'Grady A, Gallagher WM, Morrissey C, Kay EW & Watson RW 2014 The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases. Prostate 74 306-313. (doi:10.1002/pros.22752)
47. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T et al. 2010 Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12 590-598. (doi:10.1593/neo.10726)
48. Qin J, Wu SP, CreightonCJ, Dai F, XieX, ChengCM, Frolov A, AyalaG, Lin X, Feng XH et al. 2013 COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature 493 236-240. (doi:10.1038/nature11674)
49. Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM et al. 2010 Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. British Journal of Cancer 102 678-684. (doi:10.1038/sj.bjc.6605554)
50. Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A, Lopez-Berestein G, Ozpolat B & Ittmann M 2012 Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clinical Cancer Research 18 6648-6657. (doi:10.1158/1078-0432.CCR-12-2715)
51. Spencer ES, Johnston RB, Gordon RR, Lucas JM, Ussakli CH, Hurtado-Coll A, Srivastava S, Nelson PS & Porter CR 2013 Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality. Prostate 73 905-912. (doi:10.1002/pros.22636)
52. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, Shaheduzzaman S, Tan SH, Vaidyanathan G, Whitman E et al. 2008 TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27 5348-5353. (doi:10.1038/onc.2008.183)
53. Tian TV, Tomavo N, Huot L, Flourens A, Bonnelye E, Flajollet S, Hot D, Leroy X, de Launoit Y & Duterque-Coquillaud M 2013 Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2. Oncogene 33 2204-2214. (doi:10.1038/onc.2013.176)
54. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R et al. 2005 Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 644-648. (doi:10.1126/science.1117679)
55. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB et al. 2008 Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10 177-188. (doi:10.1593/neo.07822)
56. Tsang M & Dawid IB 2004 Promotion and attenuation of FGF signaling through the Ras-MAPK pathway. Science's STKE: Signal Transduction Knowledge Environment 2004 pe17. (doi:10.1126/stke.2282004pe17)
57. Vainio P, Lehtinen L, Mirtti T, Hilvo M, Seppanen-Laakso T, Virtanen J, Sankila A, Nordling S, Lundin J, Rannikko A et al. 2011 Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget 2 1176-1190.
58. Wang J, Cai Y, Ren C & Ittmann M 2006 Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Research 66 8347-8351. (doi:10.1158/0008-5472.CAN-06-1966)
59. Wang J, Cai Y, Yu W, Ren C, Spencer DM & Ittmann M 2008 Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Research 68 8516-8524. (doi:10.1158/0008-5472. CAN-08-1147)
60. Wang J, Cai Y, Shao LJ, Siddiqui J, Palanisamy N, Li R, Ren C, Ayala G & Ittmann M 2011 Activation of NF-κB by TMPRSS2/ERG fusion isoforms through Toll-like receptor-4. Cancer Research 71 1325-1333. (doi:10.1158/0008-5472.CAN-10-2210)
61. Washington MN & Weigel NL 2010 1α, 25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growthpromoting TMPRSS2:ERG gene fusion. Endocrinology 151 1409-1417. (doi:10.1210/en.2009-0991)
62. Wu L, Zhao JC, Kim J, Jin HJ, Wang CY & Yu J 2013 ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer. Cancer Research 73 6068-6079. (doi:10.1158/0008-5472.CAN-13-0882)
63. Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM, Thompson TC & Harper JW2002 Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clinical Cancer Research 8 3419-3426.
64. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y et al. 2010 An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17 443-454. (doi:10.1016/j.ccr.2010.03.018)
65. Yu W, Feng S, Dakhova O, Creighton CJ, Cai Y, Wang J, Li R, Frolov A, Ayala G & Ittmann M 2011 FGFR-4 Arg388 enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling. Clinical Cancer Research 17 4355-4366. (doi:10.1158/1078-0432.CCR-10-2858)
66. Zammarchi F, Boutsalis G & Cartegni L 2013 5′ UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer. PLoS ONE 8 e49721. (doi:10.1371/journal.pone.0049721)
67. Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H, Ittmann M, Tsai SY & Tsai MJ 2005 SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Research 65 7976-7983. (doi:10.1158/0008-5472. CAN-04-4076)